Sinovac Real World Data Shed Fresh Light On China COVID Vaccine Efficacy Debate
New Strategies Needed?
Executive Summary
New real world data for Sinovac’s COVID-19 vaccine from hard-hit Brazil could fuel fresh doubts over the efficacy of Chinese vaccines, but also raise the urgency to change current vaccination strategy.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.
J&J, Pfizer To Gain As India Fast Tracks COVID-19 Vaccines Approved By Other Regulators
J&J and Pfizer should benefit from India’s unusual move to grant accelerated approvals minus a prior local bridging study for COVID-19 vaccines granted emergency use authorizations by certain regulators or on the WHO’s emergency use list. But while this seems like a prelude to permitting private sales, where will the supplies come from?
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.